Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91,286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients.
Ma Y, Zhao C, Zhao H, Li H, Chen C, Xiang H, Zheng C, Ma C, Luo C, Qiu H, Yao Y, Hu H, Xiong B, Zhou J, Zhu H, Long Q. Ma Y, et al. Among authors: chen c. Am J Transl Res. 2019 Dec 15;11(12):7456-7470. eCollection 2019. Am J Transl Res. 2019. PMID: 31934293 Free PMC article.
Comparison of chemoembolization with CalliSpheres® microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study.
Liang B, Xiang H, Ma C, Xiong B, Ma Y, Zhao C, Yao Y, Zhang Z, Chen C, Li H, Long Q, Zhou J, Luo C, Qiu H, Hu H, Zhao H, Zhou G, Zheng C. Liang B, et al. Among authors: chen c. Cancer Manag Res. 2020 Feb 10;12:941-956. doi: 10.2147/CMAR.S187203. eCollection 2020. Cancer Manag Res. 2020. PMID: 32104076 Free PMC article.
Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
Chen C, Qiu H, Yao Y, Zhang Z, Ma C, Ma Y, Zhao C, Xiang H, Zhao H, Zheng C, Xiong B, Li H, Long Q, Zhou J, Luo C, Hu H. Chen C, et al. Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101460. doi: 10.1016/j.clinre.2020.05.008. Epub 2020 Jun 24. Clin Res Hepatol Gastroenterol. 2021. PMID: 32593695
A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma.
Zhou C, Li Y, Li J, Song B, Li H, Liang B, Gu S, Li H, Chen C, Li S, Peng C, Liu F, Xiao J, Long X, Li P, Xiong Z, Yi X, Liao W, Shi L. Zhou C, et al. Among authors: chen c. Clin Cancer Res. 2023 Aug 1;29(15):2816-2825. doi: 10.1158/1078-0432.CCR-23-0410. Clin Cancer Res. 2023. PMID: 37223896 Clinical Trial.
91,286 results
You have reached the last available page of results. Please see the User Guide for more information.